{"id":"W2403654892","doi":"10.1016/j.jtho.2016.05.008","title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Pfizer Canada; Chugai Pharmaceutical; Eisai; National Comprehensive Cancer Network; Ariad Pharmaceuticals; Genentech; AstraZeneca Canada; EMD Serono; International Association for the Study of Lung Cancer; Gilead Sciences; GlaxoSmithKline; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lung cancer; Osimertinib; Epidermal growth factor receptor; Oncology; Internal medicine; Erlotinib; Targeted therapy; Tyrosine kinase; Cancer; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003591921,0.0008921726,0.002979283,0.003229949,0.0004787756,0.001273894,0.001650427,0.00191945,0.003007547],"category_scores_gemma":[0.005366263,0.0003304408,0.002224419,0.003253079,0.0005432004,0.001188729,0.001224217,0.003457689,0.00130746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001271637,"about_ca_system_score_gemma":0.008531664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004478008,"about_ca_topic_score_gemma":0.009527245,"domain_scores_codex":[0.9988886,0.0002345375,0.0003137211,0.00009147234,0.0003907432,0.00008097147],"domain_scores_gemma":[0.996924,0.001346217,0.0004465768,0.00004963006,0.001069873,0.0001636854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000202777,0.00009186444,0.0007374881,0.04778309,0.0006443098,0.0001069463,0.00006521898,0.0003281199,0.0005176612,0.002547425,0.1145344,0.8324407],"study_design_scores_gemma":[0.0001735486,0.0001406877,0.003005417,0.0479089,0.001775859,0.0005536876,0.00009824328,0.0001139536,0.0002702302,0.002146988,0.9437673,0.00004528279],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000107318,0.9929387,0.000263979,0.003622662,0.001468234,0.00004609638,0.0002164642,0.00001270171,0.001323827],"genre_scores_gemma":[0.0006761586,0.9951565,0.0007926647,0.00214491,0.00045846,0.00005492966,0.0002778763,0.000003805326,0.0004347197],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004478008,"threshold_uncertainty_score":0.01899612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03320840595427421,"score_gpt":0.4896282325833793,"score_spread":0.4564198266291051,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}